Anbio Biotechnology Launches Advanced Diagnostic Technology in Europe

Anbio Biotechnology announced its entrance into the European medical market with its innovative AF-100 C analyzer. This portable compact fluorescent immunoassay analyzer, equipped with over 70 assays, aims to transform point-of-care testing in the EU. Anbio's expansion into Europe symbolizes a strategic effort to collaborate with EU healthcare providers and distributors, offering advanced diagnostic solutions.

Michael Lau, CEO of Anbio, emphasized the company's mission to revolutionize diagnostics with affordable and innovative solutions. The AF-100 C analyzer stands out as a comprehensive diagnostic tool, providing rapid results for a variety of tests including cancer markers, infectious diseases, and diabetes. This technology ensures quick, reliable outcomes, enhancing patient care across different clinical settings.

Anbio's launch in the EU market invites healthcare professionals to explore its diagnostic innovations. The company pledges to improve patient outcomes through its technology, which delivers accurate results within 3 to 15 minutes. Anbio's advancements in diagnostic reagents, capable of ambient storage for up to 24 months, further demonstrate its commitment to meeting the healthcare industry's needs.